Names | |
---|---|
IUPAC name
(2R,4R,5S,6S)-2-[3-[(2S,3S,4R,6S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-amino-6-carboxy-4-hydroxyoxan-2-yl]-2,3-dihydroxypropoxy]-5-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
|
|
Other names
Ganglioside G2
|
|
Identifiers | |
3D model (Jmol)
|
|
PubChem CID
|
|
|
|
Properties | |
C74H134N4O32 | |
Molar mass | 1,591.88 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
what is ?) | (|
Infobox references | |
GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans.
The relatively tumor specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.
2. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. Ahmed M, Cheung NK. FEBS Lett. 2014 Jan 21;588(2):288-97
3. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Cheung NK, Dyer MA. Nat Rev Cancer. 2013 Jun;13(6):397-411